Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Specialty Drug “Value-Based” Formulary Tiering Needs Transparency – AMA

Executive Summary

The American Medical Association is concerned that "value-based" formulary tiering structures will lack sufficient transparency regarding patients' out-of-pocket costs for specialty pharmaceuticals

You may also be interested in...

Biologic “Functional Equivalence” Being Considered By Insurers – WellPoint

Managed care plans increasingly are moving toward selecting preferred biologic agents within a therapeutic class, WellPoint VP & Chief Pharmacy Officer Robert Seidman said

PhRMA’s Evidence-Based Medicine Principles Emphasize Individual Decisions

The Pharmaceutical Research & Manufacturers of America's principles for the use of evidence-based medicine emphasize that such data be used to "empower" patients and physicians

Part D Discount Liability Coming Into Focus: CMS Releases Drug Cost Data

Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011





Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts